CJC-129 & Ipamorelin

GOALS TREATED:
Muscle Gain

Fat Loss
Injury Rehabilitation
Anti-ageing
Libido
Gut Healing
Tanning  
CJC-1295 and Ipamorelin: Synergistic Peptides for Growth Hormone Stimulation and Metabolic Health

Overview

The combination of CJC-1295 and Ipamorelin brings together two powerful peptides that stimulate growth hormone (GH) release through different mechanisms, enhancing their effectiveness. CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH), designed to increase GH release by targeting GHRH receptors. Meanwhile, Ipamorelin acts as a selective agonist for the ghrelin/growth hormone secretagogue receptor. Together, these peptides elevate GH levels by working through distinct pathways, promoting an optimal release pattern that supports lean muscle development, improved metabolism, and enhanced recovery.

Key Benefits of CJC-1295 and Ipamorelin

  • Enhances Muscle Growth and Repair: Stimulates GH release to support lean muscle mass and tissue repair.
  • Promotes Fat Loss: Boosts fat metabolism by increasing GH and Insulin-like Growth Factor 1 (IGF-1) levels.
  • Supports Bone Health: Increases bone mineral density, which can improve bone strength and reduce fracture risk.
  • Improves Sleep Quality: Promotes deeper, more restful sleep by modulating GH release.
  • Boosts Cardiovascular Health: Supports heart health by strengthening cardiovascular function.

How It Works

CJC-1295 and Ipamorelin both increase GH levels but do so through different mechanisms. CJC-1295 triggers the pituitary gland to release more GH by binding to the GHRH receptor, while Ipamorelin mimics ghrelin, enhancing GH release and reducing the inhibition of GH by somatostatin. When used together, CJC-1295 and Ipamorelin create a sustained GH release pattern with higher peaks and troughs, which supports steady growth hormone levels and improves lean muscle, bone density, and metabolic function.

Clinical Applications

  • Muscle and Bone Health: Increases muscle mass, improves bone density, and supports tissue repair, making it beneficial for recovery from injury and for strength training.
  • Metabolic Health: Aids in fat loss and helps to manage insulin resistance, contributing to improved metabolic function.
  • Anti-Aging: Promotes natural growth hormone production, which declines with age, potentially reducing the impact of age-related symptoms.
  • Recovery and Rehabilitation: Facilitates faster recovery from injuries and improves post-surgical healing through enhanced GH levels.

Research and Evidence

CJC-1295 and Growth Hormone Release

Research demonstrates that CJC-1295 can increase plasma GH levels by 2-10 times and maintains a natural pulsatile GH release, preserving the hormone's physiological benefits on bone density, protein synthesis, and muscle growth. Studies indicate that CJC-1295 may also aid in the treatment of abnormal growth and support fertility by regulating GH-related hormonal cycles.

Ipamorelin and Bone Health

Studies have shown that Ipamorelin can counteract bone density loss, particularly in cases where bone health is compromised due to prolonged glucocorticoid use. Research in rats indicates that Ipamorelin increases bone mineral density, helping to reinforce bone structure and improve overall bone health.

Ipamorelin and Muscle Growth

Research highlights that Ipamorelin mitigates the muscle-wasting effects associated with glucocorticoid use, as evidenced in animal studies where it reduced nitrogen loss and improved muscle retention. These effects make Ipamorelin valuable for patients needing long-term glucocorticoid therapy.

CJC-1295 and Fertility

Studies suggest CJC-1295 may play a role in ovulation and sperm production, with potential applications in fertility treatments. The peptide has shown positive effects on reproductive hormone cycles, making it a promising candidate for further fertility research.

Side Effects and Safety

CJC-1295 and Ipamorelin are generally well-tolerated. Some minor side effects may occur, including injection site pain, nausea, flushing, or mild dizziness. Most effects are mild and temporary. With its strong safety profile, this peptide combination is increasingly popular among those seeking targeted GH therapy with minimal side effects.

Product Information

  • Product Name: CJC-1295 and Ipamorelin
  • Supplied As: Injectable solution or nasal spray
  • Suggested Usage: Suitable for individuals seeking enhanced GH stimulation, metabolic support, and recovery benefits.
  • Applications:
    • Muscle and Bone Health
    • Metabolic Function and Fat Loss
    • Anti-Aging and Recovery
    • Improved Sleep Quality

CJC-1295 Structure

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-T yr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-L yr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg- al-Leu-Ala-Gln-Leu-Ser-Ala-ArgLys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg

Molecular Formula: C152H252N44O42

Molecular Weight: 3367.954 g/mol

PubChem CID: 56841945

CJC-1295 and Growth Hormone Release

As a derivative of GHRH, it should come as no surprise that CJC-1295 promotes the release of GH. Studies show that a single dose of CJC-1295 increase GH levels in mice by 2-10 times. Peak GH levels are reached approximately 2 hours after administration, and the effects last for about six days. Unlike other GH secretagogues, CJC-1295 preserves normal physiologic release of GH[1]. That means that the normal circadian peaks and valleys seen in GH release remain intact and that CJC-1295 is a physiologic growth hormone releasing factor. Preserving physiologic release of GH even while influencing the maximum concentration of the hormone in the bloodstream is critical to ensuring enhanced effects without increased side effects. In particular, CJC-1295 has been demonstrated to preserve growth hormone’s physiologic effects on hyperplasia, hypertrophy, bone density, blood sugar, fat metabolism, protein synthesis, and myocardial (heart cell) function.

CJC-1295 and Growth

Studies in mice without normal GHRH physiology have shown that CJC-1295 preserves normal GH release[2]. This makes the peptide potentially useful as a therapy for abnormal growth in a variety of mammalian species, humans included. Preserving normal pulsatile release of GH is critical to ensuring that proper release of downstream hormones, such as insulin-life growth factor2 (IGF-1).

CJC-1295 and Infertility

Research from the early 1990s suggests that CJC-1295 and other GRF analogues may be useful in promoting ovulation in infertile female patients. Scientists have long known that ovulation is dependent on IGF-1 and that it is also likely influenced by GH release and cycling. Research in animal models of superovulation has helped to confirm these theories by showing that both GH and IGF-1 levels rise significantly surrounding the time of ovulation. Further, these studies indicate that exogenous administration of GH secretagogues, like CJC-1295, is enough to cause appropriate ovulation[3]. There is some speculation that CJC-1295 and other analogues may even be useful in male infertility by helping to regulate sperm production. This latter hypothesis has yet to be tested.

CJC-1295 Summary

CJC-1295 is a growth hormone secretagogue designed to have a long plasma half-life and to preserve the physiologic patterns inherent in the GH axis. On both accounts, the molecule has been a success. CJC-1295 has experienced limited interest in research settings due to the advent of a number of similar molecules and because of the proprietary nature of the molecule’s structure. Now that CJC-1295 can be manufactured at will, there is likely to be renewed interest in its properties, particularly as they apply to the increasingly frustrating problem of human infertility. CJC-1295 exhibits moderate side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. CJC-1295 for sale at Peptide Sciences is limited to educational and scientific research only, not for human consumption.

WHAT IS CJC-1295?

CJC-1295 is an incredibly effective peptide which works by stimulating the release of your own body’s growth hormones (which drop quickly after the age of 30). Research has shown that CJC-1295 can increase growth hormone levels by 200-1000% and the elevated growth hormone production continued for up to 6 days.

WHAT IS IPAMORELIN?

Ipamorelin acts in a completely different way than CJC-1295 by mimicking ghrelin. This is an important distinction between both peptides because Ghrelin is responsible for initiating the breakdown of fat for use as energy as well as preventing the breakdown of muscles. Ipamorelin is cleared from the body more rapidly as its half-life is only about 2 hours.

WHY COMBINE CJC-1295 AND IPAMORELIN?

CJC-1295 and Ipamorelin are combined in therapy because they are known to work very well together. Generally, when combined, we see a 3-5 fold increase in growth hormone release over ipamorelin alone. This will increase the benefits of your peptide therapy over using a single peptide alone.

WHEN CAN I EXPECT TO SEE RESULTS?

While patients will notice some significant changes in the body after the first month, the full benefits are usually fully noticed after three to six months of therapy.

Month 1

  • Increased energy
  • Improved stamina
  • Deeper, more restful sleep

Month 2

  • Improved skin 
  • Reduced wrinkles
  • Stronger nails and hair
  • Increased metabolism

Month 3

  • Enhanced sex drive and performance
  • Improved mental focus
  • Improved joint health

Month 4

  • Continued weight reduction
  • Improved skin elasticity
  • Increased lean muscle mass

Month 5

  • Noticeably fuller, healthier hair
  • Reduced appearance of wrinkles 
  • Better skin tone
  • Continued reduction in belly fat

Month 6

  • 5-10% reduction in body fat (without exercise/diet)
  • 10% increase in lean muscle mass
  • Improved vitality due to organ regrowth

The combination of CJC 1295 and Ipamorelin has been developed because the two can act together on the pituitary and hypothalamus to increase levels of growth hormone in your body. It is done in this way to maximize the amount of growth hormone being released into your body for therapeutic benefit while acting on two separate families of receptors.

The increased volume of human growth hormone (hGH) produced by the pituitary gland have shown to cause an increase in the production of Insulin-Like Growth Factor-1 (IGF-1) by the liver and results in several health benefits such

This combination is used as a subcutaneous injection as prescribed which helps with the following

  • Energy and well-being
  • Improved bone mineral density
  • Increased lean body mass
  • Post-surgical wound healing
  • Body repair and recovery
  • Better Sleep Quality

Introduction to CJC-1295

Formula: C152H252N44O42

Structure:Tyr-D-Ala-Asp-Ala-lle-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-lle-Leu-Ser-Arg

CJC-1295, Growth Hormone Releasing Hormone (GHRH), is a synthetic secretalogue which stimulates HGH release. In the body, large amounts of growth hormone are stored in the pituitary. GHRH affects the number of secreting cells and the amount they are able to secrete. 

Usage

CJC-1295 assists in muscle growth, fat loss and sleep improvement. This peptide can also increase energy in adults, quicken metabolism and aid in anti-aging benefits.

CJC-1295 and Ipamorelin are often taken together in order to maximize the amount of growth being released into your body. Ipamorelin, while having a similar effect as CJC- 1295, only works in the body for a short term (only a few hours), while CJC-1295 takes a little while to work, but will stay in the body for over a week. The combination CJC-1295/Ipamorelin provides a steady release of natural human growth hormone production in the pituitary over time and delivers more effective results for most people compared to CJC-1295 alone. 

Mechanism of Action

CJC-1295 prompts the secretion of human growth hormone (HGH) in the body through the pituitary gland. 

HGH is necessary for many systems in the body and regulates much more than just growth.  After around age 30, the amount of HGH in the body starts to decrease and sometimes very rapidly. This decrease of HGH is an innate process and mostly responsible for lower energy and muscle mass, increased inability to build new muscle, increased trouble losing or maintaining weight, weakened immune system, decreased healing efficiency and increased signs of aging.

Administration

Mode of Administration: Subcutaneous injection to a fleshy part of the body, typically to the stomach or abdominal area.

Before administering CJC-1295/Ipamorelin always be sure to use a clean and sterile syringe.

  1. Hold the vial upright and insert the syringe in the center of the cap.
  2. Draw the plunger until you have the correct amount (see ‘Dosage’ below) in the syringe and carefully remove it.
  3. Before administering the syringe, use alcohol to cleanse the area of skin.
  4. Pinch the skin around the area to be injected, leave about 2 cm on each side.
  5. Hold the syringe at a 90 degree angle to your skin and swiftly insert the syringe.
  6. Depress the plunger fully, until the syringe is empty, and carefully draw out.

CJC-1295 take approximately 1-4 hours to reach peak serum levels, while Ipamorelin works quickly and is typically cleared out of the system rapidly as its half life is only about two hours.

Doses should be taken on an empty stomach, over one hour before and after eating.

Side Effects

CJC-1295 is known to have very subtle, if any side effects on most patients. Typically, most patients do not experience any side effects at all. However, some side effects that may occur are: sensitivity and pain at the injection site, headache, nausea, flu-like symptoms, dizziness, drowsiness, flushing of the skin, hyperactivity, difficulty swallowing and hives or rashes.

Benefits

  • Increase of bone density, which can help prevent injuries
  • Improvement of cardiovascular system strength
  • Increase of muscle mass and higher metabolism
  • Improved ability to burn fat
  • Enhanced sex drive, improving mood and overall health
  • Improved recovery time and healing of injuries
  • Strengthening of the immune system

Improvement of memory function and cognition

Referenced Citations

[1] K. Raun et al., “Ipamorelin, the first selective growth hormone secretagogue,” Eur. J. Endocrinol., vol. 139, no. 5, pp. 552–561, Nov. 1998. [PubMed]

[2] N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund, “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 11, no. 5, pp. 266–272, Oct. 2001. [PubMed]

[3] J. Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed]

[4] N. K. Aagaard et al., “Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 19, no. 5, pp. 426–431, Oct. 2009. [PubMed]

[5] E. Adeghate and A. S. Ponery, “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004. [PubMed]

[6] D. E. Beck, W. B. Sweeney, M. D. McCarter, and Ipamorelin 201 Study Group, “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients,” Int. J. Colorectal Dis., vol. 29, no. 12, pp. 1527–1534, Dec. 2014. [PubMed]

[7] B. Greenwood-Van Meerveld, K. Tyler, E. Mohammadi, and C. Pietra, “Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus,” J. Exp. Pharmacol., vol. 4, pp. 149–155, Oct. 2012. [PubMed]

[8] M. M. Fowkes, T. Lalonde, L. Yu, S. Dhanvantari, M. S. Kovacs, and L. G. Luyt, “Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor,” Eur. J. Med. Chem., vol. 157, pp. 1500–1511, Sep. 2018. [Science Direct]

[1] M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006. [PubMed]

[2] M. Alba et al., “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse,” Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006. [PubMed]

[3] A. Volpe, G. Coukos, A. Barreca, G. Giordano, P. G. Artini, and A. R. Genazzani, “Clinical use of growth hormonereleasing factor for induction of superovulation,” Hum. Reprod., vol. 6, no. 9, pp. 1228–1232, Oct. 1991. [PubMed]

[4] Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille, Martin & Pellerin, Isabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan & Bridon, Dominique. (2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog. [Research Gate]